Table S4. Patient clinical information of samples used in RNA-seq,,,,,,,,,,,,
Pt_ID,Diagnosis,Path,Ibrutinib Status at biopsy,Treatment pre-biopsy,EMMA for same set of Ibrutinib and NVP-2 (Figure 2C),RNAseq,Clinical Response,MaxConc_Viability_Mean,MaxCon_Sensitivity,,,
Pt5,MCL,"non-nodal, IgVH unmutated; blastoid subcut disease at progression (ki67 90%, myc neg, PDL1 10%)",naïve,none,,yes,R,111.5913,R,,,
Pt7,MCL,"TP53x1, IGHBCL1",refractory,"BR (refractory), RBAC (2mo), Ibrutinib (15mo)",,yes,R,72.12241,R,,,
Pt13,MCL,"del13q, IGHBCL1",refractory,"Rituximab (refractory), RCHOP (refractory), ESHAP (refractory), Velcade (refractory), R+Cladribine+Vorinostat/Ofatumomab (8mo), Ofatumomab+Cladribine+Vorinostat/Ofatumomab (7mo), Ibrutinib (22mo)",,yes,R,92.11715,R,,,
Pt17,MCL,"del13q, ATMx3, IGHBCL1",refractory,"MaxiCHOP+AutoSCT (40mo), Ibrutinib (8mo)",,yes,R,68.65691,R,,,
Pt21,MCL,"del13q, ATMx4, TP53x1, IGHBCL1",naïve,none,,yes,N/A,42.4614315,S,,,
Pt22,MCL,"no ki67 at diagnosis, on nodal relapse noted to have ki67 20%, IgVH unmutated",relapsed,"RCHOP/Rituximab maint (17mo), Velcade (2mo), Zevalin (5mo), Revlimid +Radiation (18mo), BR (18mo), Veltuzumab+Epratuzumab (6mo), Ibrutinib (42mo)",,yes,R,63.153587,R,,,
Pt24,MCL,"del13q, ATMx1, IGHBCL1",naïve,none,,yes,S,53.594967,S,,,
Pt25,MCL,"Cyto: 44~46,X,-X,+8p21,-9q32,+10p11.2,-11q21q23,t(11;14(q13,q32),dic(13;15)(p12;p12),-17,-20,idic(21q21)x2,+3~5mar[cp4]/45~47,sl,+15[cp2]; FISH: monosomy 13, ATMx1, TP53x1, IGHBCL1",naïve,"Rituximab (refractory), Revlimid+Rituximab (5mo), Revlimid (5mo)",,yes,S,21.3092985,S,,,
Pt31,MCL,IGHBCL1,naïve,none,,yes,S,39.071278,S,,,
Pt32,MCL,"TP53x1, IGHBCL1",naïve,none,,yes,S,40.089234,S,,,
Pt35,MCL,IGHBCL1,naïve,"BR (38mo), Revlimid+Rituximab/Rituximab maint (48mo)",,yes,S,110.550253,R,,,
Pt39,MCL,"non-nodal, no ki67 enum, IGVH mutated",naïve,"Revlimid/Rituximab (8mo), R+Bendamustine/Rituximab (ongoing)",,yes,N/A,83.53221,R,,,
Pt42,MCL,"blastoid, ki67 >95%, IGVH unmutated",refractory,RCHOP/RDHAP/AutoSCT (7y),,yes,R,17.2025655,S,,,
Pt45,MCL,"non-nodal, no ki67 enum, IGVH mutated",naïve,"Bendamustine+Rituximab (3y), Ibrutinb (13mo), Bortezomib (3mo), Bendamustine (2mo), CHOP (2mo), Revlimid (intol)",,yes,S,11.917903,S,,,
Pt55,MCL,"non-blastoid, ki67 15%, PDL1+",naïve,RCHOP/Rituximab (16mo),,yes,S,49.04665,S,,,
Pt58,MCL,"non-blastoid, ki67 1%, IgVH unmutated",naïve,"BR (3y), Rituximab+CEOP (3mo)",yes,yes,S,31.20549,S,,,
Pt60,MCL,"g2 FL with ki67 50% at diagnosis, DLBCL with ki67 90%, myc neg on this biopsy",naïve,"BR (24mo), Velcade+Ritux (intol)/Radiation (12mo)",yes,yes,N/A,84.19466,R,,,
Pt61,MCL,"non-blastoid, ki67 50%, IgVH borderline",naïve,Revlimid+Rituximab (intol),yes,yes,S,16.949275,S,,,
Pt62,MCL,"non-blastoid, ki67/IgVH not performed at diagnosis; at time of this biopsy ki67 15% (later at 80%)",naïve,none,yes,yes,S,103.21057,R,,,
Pt63,MCL,"no baseline data, ki67 20% at relapse, IgVH not performed",naïve,"RHyperCVAD/AutoSCT (54mo), Ibrutinib (intol), Acalabrutinib+radiation (intol)",yes,yes,S,22.820908,S,,,
Pt64,MCL,non-blastoid/ki67 20% at diagnosis; ki67 20-40% at relapse with blastoid morphology,naïve,none,yes,yes,S,52.468611,S,,,
Pt66,MCL,"non-blastoid, ki67 10%, IgVH unmutated",naïve,"RCHOP/AutoSCT (46mo), BR/Rituximab (30mo), Ibrutinib+Rituximab (2mo)",yes,yes,S,50.92593,S,,,
Pt72,MCL,"MCL in situ at diagnosis, BCL1 negative, SOX11 positive, ki67 20%, IgVH not performed",naïve,none,yes,yes,S,29.086127,S,,,
Pt76,MCL,"blastoid, ki67 50%, IgVH not performed; at relapse on this biopsy ki67 90%",intolerant,none,yes,yes,N/A,103.60686,R,,,
Pt80,MCL,"ki67 40%, igVH unmuated; called pleomorphic/blastoid at relapse (post BTK failure)",naïve,none,yes,yes,R,68.4580415,R,,,
Pt81,MCL,ki67/IgVH not performed; called blastoid by flow on this biopsy,unknown (veneotoclax empirically added),AALL1131 (4mo),yes,yes,R,84.409005,R,,,
Pt83,MCL,"non-nodal, no ki67 or IgVH testing",naïve,none,,yes,S,50.8600885,S,,,
Pt84,MCL,"non-nodal, no ki67, IgVH mutated",naïve,none,yes,yes,S,63.3247925,R,,,
Pt86,MCL,"no ki67, IgVH mutated",naïve,none,yes,yes,S,90.671055,R,,,
Pt90,MCL,"non-nodal, no ki67, IgVH mutated",naïve,none,yes,yes,S,62.0455565,R,,,
Pt91,MCL,"non-nodal, no k67, sox11 neg, IgVH mutated",naïve,none,yes,yes,N/A,64.840605,R,,,
Pt92,MCL,"ki67 10-15%, SOX11 neg, IgVH mutated",naïve,none,,yes,N/A,89.23725,R,,,
Pt101,MCL,"ki67 40%, igVH unmuated; called pleomorphic/blastoid at relapse (post BTK failure)",naïve,none,yes,,,,,,,
Pt110,MCL,"no ki67, SOX11 pos, IGVH unmutated",naïve,none,yes,,,,,,,
Pt111,MCL,"ki67 40%, SOX11 pos, IGVH not performed",naïve,none,yes,,,,,,,
Pt113,MCL,"non-nodal, no ki67, IgVH mutated",naïve,"Rituximab (refractory), RCHOP (refractory), ESHAP (refractory), Velcade (refractory), R+Cladribine+Vorinostat/Ofatumomab (8mo), Ofatumomab+Cladribine+Vorinostat/Ofatumomab (7mo), Ibrutinib+ritux (36mo)",yes,,,,,,,
Pt100,MCL,"ki67 10-15%, SOX11 neg, IgVH mutated",naïve,revlimid+rituximab (intol),yes,,,,,,,
Pt51,MCL,"non-nodal, no ki67, IgVH mutated",naïve,"Bendamustine+Rituximab (1.5y), DA-EPOCH+Rituximab/AutoSCT (1y)",yes,,,,,,,
Pt95,MCL,"ki67 30%, SOX11 pos, IgVH unmutated",naïve,none,yes,,,,,,,
Pt96,MCL,"non-nodal, no ki67, IgVH unmutated",naïve,none,yes,,,,,,,
Pt97,MCL,"non-nodal, SOX11 neg, IGVH unmutated; blastoid liver disease at relapse (Ki67 100%)",naïve,none,yes,,,,,,,
Pt98,MCL,"ki67 10-15%, SOX11 neg, IgVH mutated",naïve,revlimid+rituximab (intol),yes,,,,,,,
Pt99,MCL,"no data from diagnosis, ki67 20% at first relapse, ki67 60% on this biopsy, IgVH not performed",refractory,"RHyperCVAD/AutoSCT(73mo), Radiation+Rituximabx4 (33mo), Acalabrutinib+Rituximab (3mo)",yes,,,,,,,